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Background: We investigate whether differences in breast cancer survival in six high-income countries can be explained by
differences in stage at diagnosis using routine data from population-based cancer registries.
Methods:We analysed the data on 257 362 women diagnosed with breast cancer during 2000–7 and registered in 13 population-
based cancer registries in Australia, Canada, Denmark, Norway, Sweden and the UK. Flexible parametric hazard models were used
to estimate net survival and the excess hazard of dying from breast cancer up to 3 years after diagnosis.
Results: Age-standardised 3-year net survival was 87–89% in the UK and Denmark, and 91–94% in the other four countries. Stage
at diagnosis was relatively advanced in Denmark: only 30% of women had Tumour, Nodes, Metastasis (TNM) stage I disease,
compared with 42–45% elsewhere. Women in the UK had low survival for TNM stage III–IV disease compared with other countries.
Conclusion: International differences in breast cancer survival are partly explained by differences in stage at diagnosis, and partly
by differences in stage-specific survival. Low overall survival arises if the stage distribution is adverse (e.g. Denmark) but stage-
specific survival is normal; or if the stage distribution is typical but stage-specific survival is low (e.g. UK). International differences
in staging diagnostics and stage-specific cancer therapies should be investigated.
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There are large international differences in survival from breast
cancer, both between European countries (Berrino et al, 2007) and
worldwide (Coleman et al, 2008; Sankaranarayanan et al, 2010).
The International Cancer Benchmarking Partnership (ICBP)
analysed population-based data for women diagnosed with breast
cancer during 1995–2007 in six countries with comparable wealth,
access to universal health care and high-quality cancer registration.
Survival was highest in Sweden, Australia and Canada; inter-
mediate in Norway; lower in Denmark; and lowest in the UK.
Inequalities persisted in 2005–7, when 1-year survival was 4%
lower in the UK than in Sweden (Coleman et al, 2011).
These survival differences may be due to variations in stage at
diagnosis arising because of differences in screening, cancer
awareness or referral pathways. Alternatively, international differ-
ences may exist in stage-specific survival, indicating differences in
treatment, co-morbidity or staging accuracy. Understanding the
balance of these explanations is important to cancer control
strategies. Routinely collected data on stage are difficult to
compare, because of variations in clinical classification and coding,
and in how stage is recorded and processed by cancer registries.
Internationally recognised staging systems such as the Tumour,
Nodes, Metastasis (TNM) classification for malignant tumours
(Sobin et al, 2009) are not universally adopted, and locally defined
systems remain in use (Walters et al, 2013). Furthermore, cancer
registries do not routinely collect full information on the source of
stage data, such as the TNM version used, the timeframe after
diagnosis within which stage was recorded, whether it was defined
clinically or pathologically, and whether tumour size was recorded
before or after neo-adjuvant therapy.
Population-based comparisons of breast cancer survival by stage
have generally been limited to pair-wise contrasts between
countries with similar registration processes (Christensen et al,
2004; Jensen et al, 2004; Woods et al, 2009), or ‘high-resolution’
studies that abstract stage from the medical records of large,
representative samples of patients from cancer registries (Sant et al,
2003; Allemani et al, 2013). International high-resolution studies
are costly and time-consuming, and dependent on the accessibility
of medical records. Survival comparisons that use routinely
collected data on stage for all patients in each jurisdiction would
clearly be desirable, and may be possible if extensive quality control
is conducted (Walters et al, 2013). Here, we analyse survival with
routinely collected data for all women registered with breast cancer
in regional or national registries in these six countries, thereby
enabling the largest international comparison of survival by stage
at diagnosis.
We show how the distribution of stage at diagnosis varies in
these six countries. Age-specific and age-standardised net survival
and the excess hazard of dying up to 3 years are presented by stage
at diagnosis.
MATERIALS AND METHODS
Data. The ICBP obtained data from population-based cancer
registries in Australia, Canada, Denmark, Norway, Sweden and the
UK on 926 179 women diagnosed with breast cancer during
1995–2007 and followed up to 31 December 2007. National data
were available from Denmark and Norway. Data from Australia
and Canada were from state registries in New South Wales and
Victoria (Australia) and Alberta, British Columbia, Manitoba and
Ontario (Canada), representing 59.7% (11.4 of 19.2 million) and
64.9% (19.9 of 31.0 million) of the respective populations. For the
UK, data were obtained from England, Northern Ireland and
Wales, but not from Scotland (91.7% of the UK population; 54 of
59 million). The Swedish data were from the Uppsala-O¨rebro and
Stockholm–Gotland health regions (42.8% of the Swedish
population; 3.8 of 8.9 million), and were clinical data covering
97% of patients in the regional cancer registry.
We restricted analysis to women diagnosed with a primary,
invasive, malignant neoplasm of the breast (ICD-10 codes:
C50.0–C50.9). Tumours that were benign, in situ or of uncertain
behaviour were excluded: of the remaining 860 971 women, a
further 3.2% (27 621) were excluded because their vital status was
unknown, key dates were invalid or their cancer was registered
only from a death certificate or at autopsy. Ductal carcinoma
in situ tumours were excluded because they are not systematically
or consistently recorded by cancer registries. These are standard
exclusion criteria designed to improve internal validity and
consistency in population-based cancer survival studies. Full
details of quality control procedures have been described
(Coleman et al, 2011).
We restricted analysis of survival by stage to women diagnosed
during 2000–7 (535 537 women) when stage data were more
complete (Walters et al, 2013). We further restricted analysis to
those registries where over half of all patients had a valid stage, and
where there was no sudden change in the availability of stage over
time. This led to the exclusion of Victoria (Australia), and Alberta
and Ontario (Canada). Only 49% of patients in England had a valid
stage, but we could include five of the eight regional registries with
stage data for 50% or more of registered patients. The Danish data
were restricted to 2004–7, because earlier data were not coded to
TNM and were known to be unreliable for international
comparisons. The final sample consisted of 257 362 women.
To define ‘valid stage’, we consolidated the available data on
stage, which had been coded to a variety of classification systems.
For most countries, we could use the raw data to construct a TNM
stage. In Australia, stage was categorised as ‘localised, regional,
distant’. The Australian system is equivalent to the US Surveillance
and Epidemiology End Results Summary Stage 2000 (SEER
SS2000) (Young et al, 2001), which is more widely known and
better documented. In order to include Australia in the
comparisons, we mapped the TNM system used in all the other
countries to SEER SS2000. This mapping relied on the availability
of the component T, N and M codes, whereas in England, only
TNM stage I–IV data were available. We therefore present two sets
of analyses, one based on the TNM classification, which is more
relevant for clinicians but does not include Australia, and another
based on SEER SS2000, which enables comparisons with Australia
but excludes England (Walters et al, 2013).
Ethical approval. The study protocol was approved by the South
East Research Ethics Committee of the National Health Service on
21 April 2010 (10/H1102/19). The study protocol and the Cancer
Research UK Cancer Survival Group’s system-level security policy
at LSHTM were approved by the Ethics and Confidentiality
Committee of the National Information Governance Board on 21
April 2010 (extension of PIAG 1-05(c)2007). Registries outside the
UK obtained ethical approvals in their jurisdictions (details
available on request).
Net survival and excess mortality. Net survival is the recom-
mended method for estimating cancer survival using population-
based data (Pohar-Perme et al, 2012), because cause of death data
may be incomplete or unavailable, and death certification may not
accurately record cancer as the underlying cause of death in
comparable fashion between countries and over time (Laurenti
et al, 2000). Net survival is the survival of cancer patients, after
controlling for other causes of death (background mortality).
Background mortality is estimated by fitting life tables specific to
calendar year, region of residence, sex and single year of age
(Coleman et al, 2011).
Net survival was modelled on the log cumulative excess hazard
scale in a flexible parametric framework using the stpm2 (Lambert
and Royston, 2009) command in Stata version 12 (StataCorp LP,
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College Station, TX, USA). The availability of follow-up data
beyond the last boundary for which we want to estimate survival is
important for the stability of the model, so we present survival
estimates up to 3 years, even though we had longer follow-up for
some patients (Remontet et al, 2007). We also present the excess
hazard, the mortality counterpart to net survival, which is the
instantaneous rate of dying from breast cancer, over and above all
other causes of death, and which shows how breast cancer
mortality changes with time after diagnosis.
We ran stratified, stage-specific models, treating patients with
missing stage as a distinct category. Restricted cubic splines were
used to allow for non-linearity in the effect of age and time since
diagnosis on the excess hazard (Durrleman and Simon, 1989). We
allowed for non-proportional effects of country and age on the
hazard of dying, by introducing interactions with the splines of
time. We used a range of tests to ascertain goodness of fit and to
select our final model for each stage of diagnosis, including the
Akaike Information Criterion, log-likelihood ratio tests, and
examination of the Martingale residuals. Where possible, we
compared the results of our selected model with those from a
slightly more flexible model (e.g. by introducing an interaction
term or an extra degree of freedom in the baseline hazard). Our
selected models were robust to this increased flexibility.
Imputation of stage data. To determine the likely stage distribu-
tion among women with missing data on stage in each registry, we
conducted multiple imputation using chained equations with the
ice command in Stata 12, specifying an ordered logistic model
(Nur et al, 2010; White et al, 2011). We imputed TNM stage I–IV
and SEER SS2000. We first used logistic regression models to
determine which variables significantly predicted the pattern of
missingness or were associated with stage. These variables were
included in the imputation models. In all models, we included vital
status, the non-linear effect of the log cumulative excess hazard and
the non-linear effect of age at diagnosis. Where necessary, we also
included subsite, year of diagnosis and interactions between the log
cumulative excess hazard and age, year and subsite. We ran each
imputation model 15 times and combined the results under
Rubin’s rules (White et al, 2011).
We repeated the modelling strategy for stage-specific survival on
each of the 15 imputed data sets. The range of estimates generated
from these iterations was compared with the survival estimate
based on the observed stage data.
All-ages estimates were age-standardised using stage-specific
weights derived from the age distribution of patients in all
jurisdictions combined, in the age categories 15–44, 45–54, 55–64,
65–74, 75–84 and 85–99 years (see web appendix 1).
RESULTS
Distribution of age and stage. The mean age at diagnosis ranged
from 61 years in Australia to 63 years in the UK, Denmark and
Sweden (Table 1). The proportion of women with a valid stage
ranged from 74.7% in the UK to 92.1% in Australia. Women aged
70–99 years were more likely than younger women to be missing
stage in all countries, except Sweden (Figure 1).
Among women with TNM stage, the proportion with stage I
disease was 30.1% in Denmark, compared with 42–45% in other
countries. The proportion with stage III or IV disease ranged from
8% in Sweden to 22% in Denmark (Table 1). For SEER SS2000
stage, the proportion of women with ‘localised’ disease ranged
from 45.7% in Denmark to 69.9% in Sweden, and for ‘distant’
disease from 1.7% in the UK (Northern Ireland and Wales only) to
6.9% in Denmark.
Imputation of missing data only had a slight impact on these
stage distributions. The proportion with TNM stage III–IV was
0.1–3.8% higher after imputation, and the effect was similarly small
for SEER SS2000.
Both TNM and SEER SS2000 stage distributions were generally
more favourable for women aged 50–69 (the ‘screened age group’).
Older women were more likely to have metastatic disease than
younger women (Figure 1).
Net survival. In the analyses using TNM, age-standardised net
survival (all stages combined) at 1 year ranged from 94.3% in the
UK to 98.4% in Sweden (Table 2) and at 3 years from 87.4% in
the UK to 94.1% in Sweden (Table 3). Survival in Denmark and the
UK was significantly lower than in the other countries, at both
1 and 3 years, and it was highest in Sweden.
For women with TNM stage I–II disease, 1-year age-
standardised net survival was close to 100% in all countries. The
international range was wider for women with more advanced
disease. One-year survival for stage IV disease varied from 53.0% in
the UK to 66.9% in Sweden, a range of 13.9%. The range was also
wide for women with missing data, for whom 1-year survival
varied from 87.3% in the UK to 96.8% in Sweden. Women missing
TNM stage in Denmark and the UK had 3-year survival that was
8.6–16.1% lower than in other countries (Table 3).
International differences in overall survival (all stages com-
bined) were widest for women aged 70–99 years, at both 1 and
3 years. For example, 3-year survival was 4.1% higher in Sweden
than in the UK for women aged 50–69 years, but 12.3% higher for
women aged 70–99 years. The wider international differences for
older women were also evident for stage-specific survival.
The international pattern of survival differs between the TNM
and SEER SS2000 analyses because patients in England were only
included in the TNM analyses (51% of all TNM-staged patients,
114 557 out of 225 033), and Australian patients were only included
in the SEER SS2000 analyses (23% of all SEER SS2000 patients,
32 329 out of 142 805).
Survival for women with SEER SS2000 ‘localised’ and ‘regional’
disease was high in all countries (over 97% at 1 year). Among
women with ‘distant’ disease, 1-year survival varied from 62.4% in
Norway to 70.1% in Australia. The international range for women
with distant disease was wider at 3 years, when net survival was
significantly lower in Norway than elsewhere, intermediate in
Canada, Denmark and Sweden, and 9.1–22.5% higher in the UK
(Northern Ireland and Wales) and Australia than in the other four
countries. One- and three-year net survival for unstaged women
was lowest in Denmark and the UK.
In all six countries, women aged 70–99 years generally had
lower overall and stage-specific survival at both 1 and 3 years than
women aged 50–69 years. This difference was widest in the UK.
Women aged 70–99 years with TNM stage IV disease in the UK
had much lower 1-year survival than women aged 50–69 years
(42.2% vs 60.0%); the difference in Sweden was smaller (58.5% vs
69.1%).
Excess hazards. The stage-specific excess hazard of dying from
breast cancer for women with TNM stage I–III disease generally
rose with time since diagnosis (Figure 2). However, for patients
with distant disease, excess mortality declined slightly with time,
probably because the most frail patients, and those with the most
extensive disease, died soon after diagnosis. Among women with
TNM stage I disease, those diagnosed in Denmark had particularly
high excess mortality up to 1 year after diagnosis. Women in the
UK had relatively high excess mortality in the first year for stages
II–IV, and at all stages at 3 years.
The excess hazard rose with time since diagnosis for women
with SEER SS2000 ‘localised’ and ‘regional’ cancers in all countries,
and fell for those with ‘distant’ disease. International differences in
the excess hazard were most notable soon after diagnosis,
particularly among women with ‘regional’ disease.
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Effect of imputing stage on net survival. Imputation of missing
data on stage had little impact on survival for women with early-
stage breast cancer. For those with TNM stage III–IV, survival was
generally lower when imputed data were included. This was
especially true in the UK (five English registries, Northern Ireland,
Wales), which had the lowest stage-specific survival for all except
TNM stage I disease. For women with TNM stage IV disease,
1-year survival in the UK ranged from 50.3–51.2% in the 15
imputed data sets, whereas the range was 59.4–69.1% in the other
five countries (Figure 3). In the analyses including imputed SEER
SS2000 data, 1-year survival for women with ‘distant’ disease in the
UK (Northern Ireland, Wales) was 47.0–55.9%, compared with
61.8–70.5% elsewhere.
Women in the UK with SEER SS2000 ‘distant’ disease had
comparatively high 3-year survival (54.8%), but this was not
evident after inclusion of imputed stage data (35.6–43.0%) (see
Supplementary additional file 2).
DISCUSSION
Age-standardised net survival for women with breast cancer varied
from 94.3% in the UK to 98.4% in Sweden 1 year after diagnosis,
and from 87.4% (UK) to 94.1% (Sweden) at 3 years. International
differences were widest for women who were older, or with more
advanced disease, or with missing stage at diagnosis. The
Table 1. Number and mean age at diagnosis of breast cancer patients diagnosed in 2000–2007, country and stage at diagnosis (TNM and SEER Summary
Stage 2000), before and after multiple imputation
TNM stage SEER Summary Stage 2000
Stage Numbera
Mean
age
Observed
(%)
After
imputation
(%) Stage Numbera
Mean
age
Observed
(%)
After
imputation
(%)
Australiab All patients 32 329 60.7
Missing stage 2569 67.7 7.9
Localised 16 739 61.0 56.2 55.9
Regional 11 299 58.2 38.0 38.1
Distant 1 722 63.4 5.8 6.0
Canadac All patients 25 652 62.3 All patients 25 652 62.3
Missing stage 5341 67.8 20.8 Missing stage 5399 67.8 21.0
I 8912 61.6 43.9 41.0 Localised 12 242 61.8 60.4 57.0
II 7924 60.2 39.0 38.1 Regional 6952 58.8 34.3 35.6
III 2415 58.9 11.9 13.3 Distant 1059 62.9 5.2 7.4
IV 1060 62.9 5.2 7.6
Denmarkd All patients 16 190 63.3 All patients 16 190 63.3
Missing stage 1835 73.8 11.3 Missing stage 1835 73.8 11.3
I 4322 61.1 30.1 29.3 Localised 6557 62.2 45.7 44.8
II 6849 61.9 47.7 47.2 Regional 6810 60.8 47.4 47.7
III 2196 61.1 15.3 15.8 Distant 988 67.6 6.9 7.5
IV 988 67.6 6.9 7.7
Norway All patients 21 964 62.4 All patients 21 964 62.4
Missing stage 2873 71.2 13.1 Missing stage 2862 71.2 13.0
I 8495 60.8 44.5 43.4 Localised 10 638 61.3 55.7 54.7
II 8925 60.3 46.7 47.1 Regional 7465 60.1 39.1 39.7
III 673 66.3 3.5 3.8 Distant 999 66.7 5.2 5.7
IV 998 66.7 5.2 5.7
Swedene All patients 20 659 62.7 All patients 20 659 62.7
Missing stage 3484 65.1 16.9 Missing stage 3484 65.1 16.9
I 7758 61.1 45.2 45.2 Localised 12 003 62.0 69.9 69.9
II 8020 62.7 46.7 46.5 Regional 4678 62.3 27.2 27.2
III 903 64.7 5.3 5.3 Distant 494 66.6 2.9 2.9
IV 494 66.6 2.9 3.0
UKf All patients 140 568 63.0 All patients 26 011 63.3
Missing stage 35517 67.7 25.3 Missing stage 9163 68.6 35.2
I 44 135 60.6 42.0 40.0 Localised 10 176 60.8 60.4 56.8
II 47 738 61.2 45.4 45.4 Regional 6378 59.9 37.9 39.9
III 8663 63.3 8.2 9.2 Distant 294 66.0 1.7 3.3
IV 4515 67.6 4.3 5.4
Abbreviation: TNM¼Tumour, Nodes, Metastasis staging system.
aNumber of patients before imputation.
bAustralia: New South Wales.
cCanada: British Columbia and Manitoba.
dIn Denmark we analysed women diagnosed during 2004–7.
eSweden: Uppsala-O¨rebro and Stockholm-Gotland health regions.
fUnited Kingdom (TNM analysis): Northern Ireland, Wales and the Northern and Yorkshire Cancer Registry and Information Service, Eastern Cancer Registration and Information Centre, Oxford
Cancer Intelligence Unit, West Midlands Cancer Intelligence Unit in England; United Kingdom (SEER analysis): Northern Ireland and Wales.
BRITISH JOURNAL OF CANCER Breast cancer survival by stage at diagnosis in six countries
1198 www.bjcancer.com |DOI:10.1038/bjc.2013.6
distribution of stage at diagnosis was least favourable in Denmark,
where survival was relatively low, but stage-specific survival was
average. In contrast, the stage distribution in the UK was similar
to that in countries with higher overall survival, but survival was
lower within each category of stage. Differences in stage at
diagnosis explain some of the international variation in survival,
but other factors, such as treatment, co-morbidity and staging
procedures, must also be important (Coleman, 1999).
We analysed routinely collected data from population-based
cancer registries, handled under a single protocol, to produce a
rigorously comparable, up-to-date, international study of breast
cancer survival by stage at diagnosis for over 250 000 women.
We have described a new method to harmonise the different
clinical staging systems, and the problems of coding and
classification that remain (Walters et al, 2013). Such problems
include the high proportion of patients for whom data on stage are
not available, and the lack of consistency in how stage data are
recorded and processed by cancer registries. For the International
Association of Cancer Registries (IACR), stage at diagnosis is a
‘recommended’ (not ‘essential’) variable, and IACR guidance on
recording stage does not currently ensure standardisation of
practice (Jensen et al, 1991; Parkin, 2006).
Nonetheless, by consolidating the available stage data, we have
produced a robust stage variable for a high proportion of patients.
The stage distributions are generally consistent with previous
national and age-specific estimates (Sant et al, 2003; Allemani et al,
2010; Wishart et al, 2010), and they changed very little when stage
was imputed where it was missing. The patterns of survival by stage,
age and time since diagnosis are internally and clinically coherent.
Stage-specific survival was lower after imputation of missing
stage, particularly for late-stage disease, and especially in the UK
regions, where over 25% of patients had missing data on stage.
Older women and those with poor prognosis were particularly
likely to be in this category. The lack of change in the stage
distribution after imputation, yet lower stage-specific survival, is at
face value confusing. It arises because women with missing stage
data were on average much older than women with known stage,
and older patients generally have lower net survival, even within
each stage category. Women with missing stage data may also have
more co-morbidity or other adverse prognostic factors than
women with known stage, contributing to lower survival within
each stage. This was particularly true in the UK and Denmark,
whereas in Norway and Sweden stage appeared to be missing more
completely at random, the prognosis for women with missing stage
being closer to those with known stage, leading to smaller changes
in stage-specific survival following imputation (White et al, 2011).
A richer data set, with full data on treatment and co-morbidity,
might have enabled more precise imputations of stage, because the
main assumption behind imputation is that stage can be predicted
from other variables in the data set. Nonetheless, even when the
number of covariables is limited, multiple imputation remains the
least biased approach for handling missing data (Nur et al, 2010).
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Figure 1. Proportions of breast cancer patients with missing stage (upper figure) and cumulative stage distribution among staged patients
(lower figure). Results presented by age at diagnosis and country: TNM (left) and SEER Summary Stage 2000 (right). Notes: Denmark and Norway:
national data; Australia: New South Wales; Canada: British Columbia and Manitoba; Sweden: Uppsala-O¨rebro and Stockholm-Gotland health
regions; UK (TNM analysis): Northern Ireland, Wales and the Northern and Yorkshire Cancer Registry and Information Service, Eastern Cancer
Registration and Information Centre, Oxford Cancer Intelligence Unit, West Midlands Cancer Intelligence Unit in England; UK (SEER SS2000
analysis): Northern Ireland and Wales. In Denmark, we analysed women diagnosed during 2004–7.
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National breast cancer screening programmes for women aged
50–69/70 years were being implemented in all of these countries
except Denmark during 2000–7. Screening was initiated around
1990 (Dowling et al, 2010), although the date by which national
coverage was achieved varied, for example from 1997 in Sweden to
2005 in Norway (Autier et al, 2011). Small differences existed in
the timing and methods of screening, for example most countries
employed an annual or biennial invitation, except the UK where
women were invited every 3 years, and there was variation in the
use of digital mammography and clinical breast examination
(Dowling et al, 2010). Overall however, by 2004–5 the uptake of
screening was consistently 65–75% of eligible women in the UK,
Norway, Sweden (Dowling et al, 2010), New South Wales (Birch
et al, 2007), British Colombia and Manitoba (Public Health Agency
of Canada, 2012). Among these jurisdictions we do not consider
that small differences in the screening programmes explain
differences in the stage distribution or in stage-specific survival.
Instead, we note the consistency with which women in the
‘screened’ age-group had more favourable stage distributions than
younger and older women, and that the largest between-country
differences in survival were found among the older, ineligible,
women.
Denmark is the only country in this study that did not
implement national breast cancer screening during 2000–7. Up to
2006, just 20% of the population was covered by screening
(Jorgensen et al, 2010). Screening is associated with an increase in
the diagnosis of Stage I and II tumours (Jensena et al, 2003; Jensen
et al, 2008), as well as the ‘overdiagnosis’ of indolent invasive
cancers that might never have been diagnosed in the absence of
screening (Hackshaw, 2012; Kalager et al, 2012; Marmot et al,
2012). It is likely that the slower implementation of screening in
Denmark underlies the more advanced stage distribution in that
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Figure 2. Age-standardised excess hazard of death (per 1000 person-years, log scale) from breast cancer. Results presented by TNM or SEER
Summary Stage 2000 and time since diagnosis. Notes: (1) Denmark and Norway: national data; Australia: New South Wales; Canada: British
Columbia and Manitoba; Sweden: Uppsala-O¨rebro and Stockholm-Gotland health regions; UK (TNM analysis): Northern Ireland, Wales and the
Northern and Yorkshire Cancer Registry and Information Service, Eastern Cancer Registration and Information Centre, Oxford Cancer Intelligence
Unit, West Midlands Cancer Intelligence Unit in England; UK (SEER SS2000 analysis): Northern Ireland andWales. In Denmark, we analysed women
diagnosed during 2004–7. (2) Bubbles are scaled to represent the stage distribution at diagnosis.
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country (which is evident despite restriction of the analyses to
2004–7) (Christensen et al, 2004). It may also explain the
lower survival of women with Stage I tumours compared with
that group of women in other countries, where more women with
‘overdiagnosed’ indolent invasive tumours may have been
included.
It is possible that the overall relatively low net survival in
Denmark arises in small part because of lead time bias in the other
countries, wherein diagnosis is brought forward by screening,
so that survival from the time of diagnosis is longer, regardless of
whether screening actually extended life. However, this cannot
fully explain low survival in Denmark, because survival in
Denmark is relatively low even among non-screened age-groups.
It has been shown that lower survival in England than in
Sweden and Norway arises mainly in the first few months after
diagnosis (Møller et al, 2010; Lambert et al, 2011). Low survival in
the first year may indicate delayed diagnosis, and it has led to
promotion of ‘awareness of symptoms and early detection as the
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Figure 3. Age-standardised 1-year net survival for women diagnosed with breast cancer during 2000–7. Results presented by stage at diagnosis
and country, using known stage and imputed stage: TNM (upper figure) and SEER Summary Stage 2000 (lower figure). x¼ survival estimate
derived from women with known stage. ¼ range of survival estimates derived for all women after imputation of stage where it was missing
(see text). Notes: Denmark and Norway: national data; Australia: New South Wales; Canada: British Columbia and Manitoba; Sweden: Uppsala-
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in England; UK (SEER SS2000 analysis): Northern Ireland and Wales. In Denmark, we analysed women diagnosed during 2004–7.
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main strategy to improve breast cancer survival in the United
Kingdom’ (Møller et al, 2010). Given the ecological studies cited
above, we might expect later diagnosis to lead to a later stage
distribution, but the stage distribution in the UK is actually fairly
average among these countries, and it cannot fully explain the
lower survival of UK breast cancer patients.
International differences in stage-specific survival may be
explained by differences in treatment. Previous studies have
identified differences between European countries in the propor-
tion of women who receive ‘standard care’ for breast cancer
(Allemani et al, 2010), especially a lower proportion receiving
surgery in the UK (Sant et al, 2003). Given that the largest
differences in survival were found for women with metastatic
disease, we would expect this to be largely driven by differences in
the use of systemic therapies (Koscielny et al, 2009). Further
research is under way to determine whether differences in breast
cancer treatment between these six countries in 2000–7 could help
explain the inequalities in survival.
International differences in stage-specific survival may also
reflect differences in the intensity and accuracy of staging. In the
UK, it is recommended that asymptomatic women should not
undergo staging investigations such as whole body bone and CT
scans for metastatic disease (National Institute for Health and
Clinical Excellence, 2012). If women with asymptomatic metastases
are systematically diagnosed as having non-metastatic disease, this
could help explain our finding of lower survival than elsewhere
among women with both stage III and IV tumours in the UK
(stage migration) (Feinstein et al, 1985). Previous studies have
highlighted less aggressive staging in the UK than in other
European countries (Sant et al, 2003). To ensure that future studies
can control correctly for differences in the intensity of staging
investigations between countries, details of these procedures should
be systematically captured by cancer registries.
The largest international differences in survival were found among
older women or those who were not staged, who had particularly low
survival in the UK and Denmark. Treatment recommendations are
less well defined for older women, who are rarely included in clinical
trials and who often have more complex co-morbidities (Bastiaannet
et al, 2010). Women in the UK and Denmark may be staged less
often than in other countries if they are particularly frail and could be
considered liable to suffer from invasive staging investigations.
Unstaged women may also have shorter survival because treatment
guidelines are less clear (Voogd and Coebergh, 2010; Wishart et al,
2010). Some of these women may actually have been staged, but the
clinical data not transmitted to the cancer registry. The channels for
reporting clinical information on stage to cancer registries should be
improved to enable better international comparisons of cancer
survival.
CONCLUSIONS
International variation in breast cancer survival is partly explained
by stage at diagnosis. This was most clearly true in Denmark,
where the stage distribution was most adverse and where overall
survival was lower than in any other country except the UK.
The national roll-out of mammographic screening in Denmark
from 2007 will be expected to increase the proportion of women
diagnosed at an early stage. In the UK, by contrast, the stage
distribution was relatively favourable, but stage-specific survival
was lower than in other countries. This suggests that the low
survival in the UK must be explained by other factors, such as the
intensity and accuracy of staging, and access to or the effectiveness
of stage-specific treatment. Australia and Sweden had quite
favourable stage distributions at diagnosis and relatively high survival
at all stages of disease. There is scope for other countries to learn
from health policies and clinical practice in these countries. Women
with early-stage disease in Canada and Norway had similar survival
to that seen elsewhere, but those with late-stage disease had lower
survival than in Australia and Sweden: the treatment of these women
should be investigated, as should the relatively high proportion of
women with TNM stage III disease in Canada.
The completeness and comparability of stage data routinely
collected by population-based cancer registries needs considerable
improvement to facilitate comparisons of survival by stage. Such
data enable larger, more timely, more representative and more
affordable comparisons of cancer survival than any other approach
and they can be invaluable in monitoring the success of cancer
control strategies. To this end, IACR should now identify stage as
an ‘essential’ data item for collection by population-based cancer
registries, and clinicians and registry staff should ensure that data
on stage at diagnosis are complete, standardised and comparable
between countries. Clinicians should be encouraged to conform to
a single international staging system such as TNM. Meanwhile, the
Union for International Cancer Control should ensure that the
TNM system achieves a balance between meeting clinical demands
for detail and retaining the simplicity required for surveillance of
cancer survival worldwide.
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